Axsome Therapeutics is trading at $212.31, up +4.04%, rebounding after falling 5.78% on September 15.

  • Axsome is presenting at the H.C. Wainwright Global Investment Conference on September 16.
  • No new company-specific catalyst has been confirmed.
  • Broader market sentiment is modestly positive, while biotechnology remains weak, leaving the precise catalyst unclear.